Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.53 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133967 | 1.00 | KDM1A (0.53) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL4133964 | 1.00 | KDM1A (0.53) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL806142 | 0.82 | FFAR1 (0.59) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL21501045 | 0.82 | FFAR1 (0.59) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL455245 | 0.82 | FFAR1 (0.59) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL24890441 | 0.82 | KDM1A (0.50) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL437376 | 0.82 | FFAR1 (0.59) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL799467 | 0.82 | FFAR1 (0.59) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL455246 | 0.82 | FFAR1 (0.59) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL4719284 | 0.82 | FFAR1 (0.59) | KDM1AMAOBKCNH2RCOR1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2019-03-19 | — | — | US | disclosed |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS SA (ES) | 2018-05-10 | — | — | US | disclosed |
| US-9944601-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2018-04-17 | — | — | US | disclosed |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
| US-9708309-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2017-07-18 | — | — | US | disclosed |
| US-9676701-B2 | Cyclopropylamine derivatives useful as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2017-06-13 | — | — | US | disclosed |
| US-9670136-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2017-06-06 | — | — | US | disclosed |
| US-8853390-B2 | Processes for preparing 1,2-substituted cyclopropyl derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | KDM6A, KDM1B, KDM1A | KDM1A 3/4885MAOB 66/4885KCNH2 1430/4885 |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | KDM1A 3/4885MAOB 66/4885KCNH2 1430/4885 |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | HRH3, HRH4, HRH1 | KDM1A 1116/4885MAOB 976/4885KCNH2 1253/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 165/4885KCNH2 1811/4885 |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 147/4885KCNH2 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.